TGA / PMDA / NMPA · Asia-Pacific
fluticasone — TGA / PMDA / NMPA regulatory status
fluticasone regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 3
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 1 published clinical program and 0 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| Fluticasone furoate | Phase 3 | GSK Glaxo Smith | NCT01622231 |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of fluticasone?
fluticasone currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get fluticasone regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to fluticasone?
This spoke lists 1 published program associated with fluticasone in our pipeline index.